PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

brodalumab

Verify with FDA → · CMS NADAC pricing →

Brand names: Siliq

Anti-IL-17 Receptor Monoclonal Antibody Rx

Siliq is a medicine used to treat moderate to severe plaque psoriasis. It is for adults who can use systemic therapy or phototherapy and have not responded well to other treatments.

What it does

Siliq treats moderate to severe plaque psoriasis.

Common side effects

Joint pain, Headache, Feeling tired

Key warnings

Siliq may cause suicidal thoughts and behavior.

How It Works

Siliq blocks a protein called interleukin-17 receptor A (IL-17RA). This protein is involved in causing inflammation in psoriasis. By blocking it, Siliq helps reduce the symptoms of psoriasis.

How to Take It

You will receive Siliq as an injection under your skin. The usual dose is 210 mg. You will get an injection at Weeks 0, 1, and 2. After that, you will get an injection every 2 weeks. If you don't see improvement after 12 to 16 weeks, talk to your doctor about stopping treatment.

Pregnancy & Breastfeeding

It is not known if Siliq can harm your unborn baby. Tell your doctor if you are pregnant or plan to become pregnant. It is also not known if Siliq passes into breast milk. Talk to your doctor about the risks and benefits of breastfeeding while using Siliq.

Missed Dose

If you miss a dose of Siliq, inject it as soon as you remember. Then, continue with your regular schedule.

Storage

Store Siliq in the refrigerator at 36°F to 46°F (2°C to 8°C) in its original carton to protect it from light.

Side Effects (from patient reports)

Based on 1,858 FDA adverse event reports.

Psoriasis
471
Drug Ineffective
230
Joint pain
181
Tiredness
163
Psoriatic arthritis
156
Problem with how the product is used on purpose
146
Problem with missing a dose of the product
132
Disease coming back
129
Headache
126
Treatment stopped temporarily
124

FDA Adverse Event Report Analysis

Detailed analysis of 1,890 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2013–2025.

Total Reports

1,890

Death-Related Reports

133

Hospitalization Reports

535

Top Indication

Psoriasis

Gender Distribution

Female 831 (46%)
Male 962 (54%)

Age Distribution

0–17 39
18–44 332
45–64 646
65–74 311
75+ 179

Most Reported Adverse Reactions (FAERS)

# Reaction Reports
1 PSORIASIS 471
2 DRUG INEFFECTIVE 230
3 ARTHRALGIA 181
4 FATIGUE 163
5 PSORIATIC ARTHROPATHY 156
6 INTENTIONAL PRODUCT USE ISSUE 146
7 PRODUCT DOSE OMISSION ISSUE 132
8 DISEASE RECURRENCE 129
9 HEADACHE 126
10 THERAPY INTERRUPTED 124
11 OFF LABEL USE 116
12 INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 115
13 DIARRHOEA 91
14 COVID-19 87
15 PAIN IN EXTREMITY 87

Reactions in Death Reports

DEATH 72
PSORIASIS 11
INTENTIONAL PRODUCT USE ISSUE 9
MULTIPLE ORGAN DYSFUNCTION SYNDROME 8
PRODUCT DOSE OMISSION ISSUE 8
BLOOD PRESSURE INCREASED 7
PNEUMONIA 7
FALL 6
ASTHENIA 5
COUGH 5

Reactions in Hospitalization Reports

PSORIASIS 147
HOSPITALISATION 57
PRODUCT DOSE OMISSION ISSUE 57
DRUG INEFFECTIVE 50
ARTHRALGIA 45
INTENTIONAL PRODUCT USE ISSUE 45
THERAPY INTERRUPTED 43
FALL 41
OFF LABEL USE 40
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 37

Source: FDA FAERS (Adverse Event Reporting System) FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation

Serious Warnings

Siliq may cause suicidal thoughts and behavior. Tell your doctor if you have a history of depression or suicidal thoughts. If you have new or worsening suicidal thoughts or depression, get medical help right away. Siliq is only available through a special program because of this risk.

Known Drug Interactions

Therefore, upon initiation or discontinuation of SILIQ in patients who are receiving concomitant drugs which are CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for effect (e.g., for warfarin) or drug concentration (e.g., for cyclosporine) and consider dosage modification of the CYP450 substrate [see Clinical Pharmacology ( 12.3 )].

Mechanism: Brodalumab can change how your liver enzymes break down other medicines like warfarin. This can cause the amount of warfarin in your body to go up or down.

What to do: Your doctor should monitor your blood clotting tests closely and may need to adjust your dose when you start or stop this medicine.

Therefore, upon initiation or discontinuation of SILIQ in patients who are receiving concomitant drugs which are CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for effect (e.g., for warfarin) or drug concentration (e.g., for cyclosporine) and consider dosage modification of the CYP450 substrate [see Clinical Pharmacology ( 12.3 )].

Mechanism: Brodalumab may affect the liver enzymes that process cyclosporine, which can lead to changes in the amount of medicine in your blood.

What to do: Your doctor should check your blood levels of cyclosporine and may need to change your dose when you start or stop this treatment.

Common Questions

What should I do before starting Siliq?
Your doctor will check you for tuberculosis (TB) before you start Siliq.
Can Siliq cause allergic reactions?
Yes, serious allergic reactions, including anaphylaxis, can occur. Stop using Siliq and get medical help right away if you have a reaction.
What if I get an infection while taking Siliq?
Tell your doctor right away if you get any signs of an infection.
Can I get vaccines while using Siliq?
Avoid live vaccines while using Siliq.
What if I have new or worsening depression while on Siliq?
Contact a mental health professional immediately.
How long can Siliq be stored at room temperature?
Siliq can be stored at room temperature for up to 14 days.
What does Siliq look like?
Siliq is a clear to slightly opalescent, colorless to slightly yellow solution.
How is Siliq given?
Siliq is given as an injection under the skin (subcutaneous injection).
What if Siliq doesn't work after a few months?
If you don't see improvement after 12-16 weeks, your doctor may stop the treatment.
Can Siliq affect other medicines I'm taking?
Yes, Siliq might affect how other medicines work. Tell your doctor about all the medicines you take.
What are the common side effects of brodalumab?
The most commonly reported side effects of brodalumab include Joint pain, Headache, Feeling tired, Diarrhea, Pain in the throat. Based on 1,858 FDA adverse event reports. Always consult your healthcare provider about potential side effects.
Does brodalumab interact with other medications?
Yes, brodalumab has 2 known drug interactions. Notable interactions include warfarin, cyclosporine. Always inform your doctor about all medications you are taking.
What drug class is brodalumab?
brodalumab belongs to the Anti-IL-17 Receptor Monoclonal Antibody drug class. It requires a prescription (Rx). Siliq treats moderate to severe plaque psoriasis.
Is brodalumab safe during pregnancy?
It is not known if Siliq can harm your unborn baby. Tell your doctor if you are pregnant or plan to become pregnant. Always consult your healthcare provider before using any medication during pregnancy or breastfeeding.

Related Medications in Anti-IL-17 Receptor Monoclonal Antibody

Other drugs grouped near brodalumab — same-class peers and common alternatives.

Compare brodalumab vs adapalene side-by-side →

Medication Guides

Related Health & Safety Data

Save on brodalumab

Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.

Disclosure: This link may earn us a commission at no extra cost to you. See our terms.

What the FDA Data Shows for brodalumab

The FDA label for brodalumab (sold under brand names such as Siliq) classifies it as a prescription-only medication in the Anti-IL-17 Receptor Monoclonal Antibody class. Siliq treats moderate to severe plaque psoriasis. Official labeling lists 11 commonly reported side effects, including Joint pain, Headache, Feeling tired.

Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 1,858 voluntary reports. The database also lists 2 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated minor severity. Acquisition-cost data is surveyed weekly by CMS and updated as manufacturers report changes.

Report counts do not establish causation — a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information further shape supply and switching decisions. This page summarizes public FDA data for educational purposes only and is not a substitute for professional medical advice — always consult a licensed healthcare provider before starting, stopping, or changing any medication.

Data Sources

Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS).

FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. Always consult a healthcare professional before making medication decisions.

Last updated: February 11, 2026

All federal data sources used on this page